These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23846930)

  • 1. Biomarkers in neuroendocrine tumors.
    Duque M; Modlin IM; Gupta A; Saif MW
    JOP; 2013 Jul; 14(4):372-6. PubMed ID: 23846930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on novel therapies for pancreatic neuroendocrine tumors.
    Oberstein PE; Saif MW
    JOP; 2012 Jul; 13(4):372-5. PubMed ID: 22797392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
    Stevenson R; Libutti SK; Saif MW
    JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic neuroendocrine tumors: entering a new era.
    Oberstein PE; Remotti H; Saif MW; Libutti SK
    JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets.
    Capdevila J; Meeker A; García-Carbonero R; Pietras K; Astudillo A; Casanovas O; Scarpa A
    Cancer Metastasis Rev; 2014 Mar; 33(1):345-51. PubMed ID: 24375391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of poorly differentiated neuroendocrine carcinoma of the pancreas.
    Gupta A; Duque M; Saif MW
    JOP; 2013 Jul; 14(4):381-3. PubMed ID: 23846932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
    Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
    Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
    Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors.
    Oberstein PE; Saif MW
    JOP; 2012 Jul; 13(4):368-71. PubMed ID: 22797391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
    Singh S; Law C
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy.
    Franco M; Pàez-Ribes M; Cortez E; Casanovas O; Pietras K
    Horm Metab Res; 2011 Nov; 43(12):884-9. PubMed ID: 21960459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
    Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors.
    Burney S; Khawaja KI; Saif MW; Masud F
    JOP; 2014 Jul; 15(4):313-6. PubMed ID: 25076330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Oberstein PE; Saif MW
    JOP; 2011 Jul; 12(4):358-61. PubMed ID: 21737896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors.
    O'Toole D; Couvelard A; Rebours V; Zappa M; Hentic O; Hammel P; Levy P; Bedossa P; Raymond E; Ruszniewski P
    Endocr Relat Cancer; 2010 Dec; 17(4):847-56. PubMed ID: 20570957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Xu X; Strimpakos AS; Saif MW
    JOP; 2011 Jul; 12(4):325-9. PubMed ID: 21737888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in pancreatic adenocarcinoma.
    Joza N; Saif MW
    JOP; 2014 Jul; 15(4):308-9. PubMed ID: 25076328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
    Gloesenkamp C; Nitzsche B; Lim AR; Normant E; Vosburgh E; Schrader M; Ocker M; Scherübl H; Höpfner M
    Int J Oncol; 2012 May; 40(5):1659-67. PubMed ID: 22246317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
    Gilbert JA; Adhikari LJ; Lloyd RV; Rubin J; Haluska P; Carboni JM; Gottardis MM; Ames MM
    Endocr Relat Cancer; 2010 Sep; 17(3):623-36. PubMed ID: 20385747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin-like growth factor-1 increases intracellular calcium concentration in human primary neuroendocrine pancreatic tumor cells and a pancreatic neuroendocrine tumor cell line (BON-1) via R-type Ca2+ channels and regulates chromogranin a secretion in BON-1 cells.
    Mergler S; Strauss O; Strowski M; Prada J; Drost A; Langrehr J; Neuhaus P; Wiedenmann B; Ploeckinger U
    Neuroendocrinology; 2005; 82(2):87-102. PubMed ID: 16424676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.